Nonpartisan civic infrastructure
AllCiv·Legis1
·

S. 476

BillFederalSenateIn Committee
To amend title XI of the Social Security Act to protect access to genetically targeted technologies.
About This Bill
Committee
Latest Action · February 16, 2023
Read twice and referred to the Committee on Finance.
Congress
118th (2023–2025)
Introduced
February 16, 2023
Cosponsors (3)
0D 3R
View PDF ↗

Summary

Highlight any text to annotate
Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.